Arecor Therapeutics (LON:AREC) Stock Price Up 3.3% – Time to Buy?

Arecor Therapeutics plc (LON:AREC) rose 3.3% during mid-day trading on Wednesday . The stock traded as high as GBX 70 and last traded at GBX 68.15. Approximately 6,969 shares changed hands during trading, a decline of 60% from the average daily volume of 17,440 shares. The stock had previously closed at GBX 66.

Arecor Therapeutics Price Performance

The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The firm has a market cap of £24.89 million, a P/E ratio of 32.96 and a beta of -0.18. The firm has a 50-day simple moving average of GBX 67.07 and a 200-day simple moving average of GBX 74.17.

Arecor Therapeutics (LON:AREC) last posted its quarterly earnings data on Monday, April 13th. The company reported GBX 2 earnings per share for the quarter. The firm had revenue of GBX 171 million during the quarter. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%. As a group, analysts forecast that Arecor Therapeutics plc will post -0.35 EPS for the current year.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.